# BNT324

Source: https://onco.cc/drugs/bnt324/  
OnCo record `bnt324` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BNT324 is an experimental antibody-drug conjugate from BioNTech SE in phase 3 trials for prostate cancer and non-small-cell lung cancer, aimed at B7-H3.

## Summary

BNT324 (DB-1311) is an antibody-drug conjugate developed by BioNTech SE. Its target is B7-H3 (the sponsor names B7-H3). The sponsor states: BNT324 (DB-1311) is an antibody-drug conjugate targeting B7-H3, given as an intravenous infusion in 21-day cycles; a phase 3 trial compares it with docetaxel in metastatic castration-resistant prostate cancer. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07365995 (A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer), in prostate cancer and non-small-cell lung cancer. The largest, NCT07365995, plans to enrol 736 participants with primary completion expected 2031-02. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: DB-1311
- Modality: ADC
- Mechanism: BNT324 (DB-1311) is an antibody-drug conjugate targeting B7-H3, given as an intravenous infusion in 21-day cycles; a phase 3 trial compares it with docetaxel in metastatic castration-resistant prostate cancer.

## Sources

- ClinicalTrials.gov: trials of BNT324: https://clinicaltrials.gov/search?intr=DB-1311

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [B7-H3](https://onco.cc/targets/b7h3/)
- companies: [BioNTech](https://onco.cc/companies/biontech/)
- trials: [A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer](https://onco.cc/trials/nct06892548/), [A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct05914116/), [A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer](https://onco.cc/trials/nct07365995/), [DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct06953089/)

---
JSON: https://onco.cc/api/v1/entities/bnt324.json